For Investors & Analysts
Backed by Neural Cloud Solutions — one patented cardiac-AI engine serving three markets (regulated ECG monitoring, consumer wearables, and cardiac safety in clinical research) — AI/ML Innovations Inc. is committed to delivering long-term shareholder value while improving cardiac outcomes across global markets.
AIML
AIMLF
42FB
Why Invest in AIML
We are pioneering the future of health intelligence — developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights. The platform compounds as more signal flows through it.
01
Validated outcomes on real clinical data.
Neural Cloud's MaxYield™ is trained under expert oversight and clinically validated on a proprietary, expert-annotated edge-case corpus by Drs. Paul Dorian and Martin Green — with a billion heartbeats already processed.
02
Software-margin economics on commodity hardware.
Device-agnostic by design — no manufacturing exposure, no rip-and-replace. Neural Cloud licenses one patented engine across regulated monitoring, consumer wearables, and clinical research.
03
A platform play across three markets.
One public company, one operating business, three markets — regulated ECG monitoring, consumer wearables, and cardiac safety in clinical research.
Press Releases
Cross-posted to SEDAR+, the CSE listing page, and our investor email list within minutes of publication. The most-recent six are below.
October 2, 2026
AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
October 1, 2026
AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield™ ECG Services
September 29, 2026
AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield™ Clinical Pilots
September 21, 2026
AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform
September 1, 2026
AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs
August 18, 2026
AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield™ Pilot
The Pulse · Monthly Newsletter
The Pulse
"The Pulse" Summer 2026, The Latest from AI/ML Innovations Inc.
September 9, 2026
The Pulse
"The Pulse" Newsletter - April, 2026
May 28, 2026
The Pulse
"The Pulse" February, 2026 AIML Recap
March 5, 2026
FULL RECORDING · 1:08:31
2025 Shareholder Update & 2026 Outlook.
Paul Duffy walks through milestones across product development, commercial traction, and regulatory progress — alongside the 2026 roadmap. Live Q&A closes the session.
Corporate Governance
Paul Duffy
Executive Chairman & CEO
Michael Diamond
Independent Director
Jared Adelstein
Independent Director
FILINGS
Annual and interim financials, MD&A, material change reports, technical and business acquisition reports — all hosted on SEDAR+ and the CSE listing page.
Open on CSE / SEDAR+
AGM & Proxy materials
Available years with documents
Charters & Policies
Capital Structure
As of September 1, 2026.
Updated alongside each material change. Refer to the CSE listing page for trading and the most current MD&A for full per-class detail.
291.05
M
Common Shares Outstanding
3.0
M
RSUs
17.3
M
Options
207.3
M
Warrants
518.7
M
Total fully diluted 518
AI/ML Innovations Inc.
AIML-Innovations.com
Subsidiaries
© 2026 AI/ML Innovations Inc. · CSE: AIML
AI. Innovation. Impact.
